Efficacy and safety of intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndromes: a meta-analysis of
2 hours ago
- #percutaneous coronary intervention
- #glycoprotein IIb/IIIa inhibitors
- #acute coronary syndrome
- Intralesional glycoprotein IIb/IIIa inhibitor (GPI) administration during PCI for ACS shows improved postprocedural TIMI grade 3 flow compared to intracoronary delivery.
- No significant differences were found in major adverse cardiovascular events, bleeding, or thrombocytopenia between intralesional and intracoronary GPI routes.
- The analysis included nine randomized controlled trials with 509 patients in the intralesional group and 486 in the intracoronary group.
- After statistical adjustment, only TIMI grade 3 flow remained significantly better with intralesional administration; other metrics like corrected TIMI frame count and ST-segment resolution did not show significant differences.
- Intracoronary GPI administration after PCI has previously shown better outcomes than intravenous use, but this meta-analysis focuses on comparing intracoronary versus intralesional delivery during PCI.